Ipilimumab in the treatment of metastatic melanoma: management of adverse events

Recently, “ipilimumab,” an anti-cytotoxic T-lymphocyte antigen-4 (CTLA-4) monoclonal antibody, has been demonstrated to improve overall survival in metastatic melanoma. “CTLA-4” is an immune-checkpoint molecule that downregulates pathways of T-cell activation. Ipilimumab, by targeting CTLA-4, is abl...

Descripción completa

Detalles Bibliográficos
Autores principales: Della Vittoria Scarpati, Giuseppina, Fusciello, Celeste, Perri, Francesco, Sabbatino, Francesco, Ferrone, Soldano, Carlomagno, Chiara, Pepe, Stefano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2014
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3933725/
https://www.ncbi.nlm.nih.gov/pubmed/24570590
http://dx.doi.org/10.2147/OTT.S57335

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3933725/
https://www.ncbi.nlm.nih.gov/pubmed/24570590
http://dx.doi.org/10.2147/OTT.S57335

Ejemplares similares